Drug intelligence / Profile preview

Azelnidipine

Development stage: Phase 4
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

Azelnidipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension. It works by inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation and a decrease in blood pressure. Azelnidipine is known for its gradual onset and long-lasting antihypertensive effect without significantly increasing heart rate. It also exhibits cardio-protective, neuroprotective, and anti-atherosclerotic properties. Developed by Daiichi Sankyo, it is marketed under various brand names including Calblock.

Brand names: CalblockBeiqiRezaltas HDRezaltas LD
Other names: AzelnidipinoAzelnidipinum

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Azelnidipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azelnidipine.

Explore the full profile